We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition).
- Authors
Liu, Xiufeng; Lu, Yinying; Zhou, Weiping; Peng, Tao; Zhou, Jie; Bi, Huaqiang; Xia, Feng; Chen, Xiaoping
- Abstract
Background: Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC. Summary: To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the "Delphi" consensus formation method, and finally revised and completed the "Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)" on the basis of the 2021 edition. Key Messages: This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.
- Subjects
IMMUNE checkpoint inhibitors; IMMUNE checkpoint proteins; HEPATOCELLULAR carcinoma; MEDICAL research; CLINICAL medicine
- Publication
Liver Cancer (2235-1795), 2024, Vol 13, Issue 4, p355
- ISSN
2235-1795
- Publication type
Article
- DOI
10.1159/000535496